SCHEMBL955091

SCHEMBL955091

Cc1cc2nc(COc3ccccc3Cl)cc(O)n2n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.49
MAPT P10636 5/20 0.41
KDM4E B2RXH2 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PKM P14618 1/20 0.39
NPC1 O15118 3/20 0.38
TP53 P04637 2/20 0.38
RAB9A P51151 2/20 0.38
HPGD P15428 2/20 0.38
MITF O75030 1/20 0.38
XBP1 P17861 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
HTT P42858 1/20 0.38
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL958613 0.87 MRGPRX4 (0.50) SMN1; SMN2NPC1RAB9AHPGDLMNA
SCHEMBL956573 0.81 FFAR1 (0.50) FFAR1MAPTRAB9APOLBLMNA
SCHEMBL956425 0.73 KDM4E (0.39) KDM4EMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL956589 0.73 FFAR1 (0.37) FFAR1MAPTKDM4EPOLBALDH1A1
SCHEMBL3339372 0.70 PTGDR2 (0.40) MAPTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL954380 0.68 RXFP1 (0.47) MAPTKDM4ESMN1; SMN2PKMALDH1A1
SCHEMBL3344200 0.68 MAPT (0.43) MAPTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL27801547 0.68 TSHR (0.46) FFAR1MAPTKDM4EMEN1KMT2A
SCHEMBL14211728 0.68 KDM4E (0.42) MAPTKDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL955471 0.67 DPP4 (0.38) KDM4EKMT2ASMN1; SMN2RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009429-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 NOVARTIS AG (CH) 2011-01-13 US disclosed
EP-2257552-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 Novartis AG (CH) 2010-12-08 EP disclosed
WO-2009106539-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 NOVARTIS AG (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009429-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 CXCR2, CXCR1, CXCR3 FFAR1 731/4885MAPT 4866/4885KDM4E 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.